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Abstract
We determined whether over-expression of one of the three genes
involved in reverse cholesterol transport, apolipoprotein (apo) AI,
lecithin-cholesterol acyl transferase (LCAT) and cholesteryl ester
transfer protein (CETP), or of their combinations influenced the
development of diet-induced atherosclerosis. Eight genotypic groups
of mice were studied (AI, LCAT, CETP, LCAT/AI, CETP/AI, LCAT/
CETP, LCAT/AI/CETP, and non-transgenic) after four months on an
atherogenic diet. The extent of atherosclerosis was assessed by mor-
phometric analysis of lipid-stained areas in the aortic roots. The
relative influence (R2) of genotype, sex, total cholesterol, and its main
sub-fraction levels on atherosclerotic lesion size was determined by
multiple linear regression analysis. Whereas apo AI (R2 = 0.22, P <
0.001) and CETP (R2 = 0.13, P < 0.01) expression reduced lesion size,
the LCAT (R2 = 0.16, P < 0.005) and LCAT/AI (R2 = 0.13, P < 0.003)
genotypes had the opposite effect. Logistic regression analysis re-
vealed that the risk of developing atherosclerotic lesions greater than
the 50th percentile was 4.3-fold lower for the apo AI transgenic mice
than for non-transgenic mice, and was 3.0-fold lower for male than for
female mice. These results show that apo AI overexpression decreased
the risk of developing large atherosclerotic lesions but was not suffi-
cient to reduce the atherogenic effect of LCAT when both transgenes
were co-expressed. On the other hand, CETP expression was suffi-
cient to eliminate the deleterious effect of LCAT and LCAT/AI
overexpression. Therefore, increasing each step of the reverse choles-
terol transport per se does not necessarily imply protection against
atherosclerosis while CETP expression can change specific athero-
genic scenarios.
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Introduction
Numerous epidemiological studies have
demonstrated an inverse relationship between
HDL-cholesterol and coronary heart disease
(1,2). A meta-analysis of clinical trials data
and other studies has revealed that an in-
crease of 1 mg/dl in HDL-cholesterol was
accompanied by a 2 and 3% reduction in
cardiovascular risk in men and women,
respectively (1). However, high levels of
HDL-cholesterol are not always protective
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(3,4), and patients with low HDL-choles-
terol levels do not necessarily show prema-
ture atherosclerosis (5). Thus, the HDL-cho-
lesterol turnover rate rather than its steady-
state plasma concentration seems to be more
relevant for protection against atherosclero-
sis.
Proteins involved in reverse cholesterol
transport (RCT) can markedly modify the
turnover rate of HDL-cholesterol and the
development of atherosclerosis. RCT is an
efficient mechanism for removing excess
cholesterol from tissues to the liver for ex-
cretion. This system involves an efflux of
free cholesterol from cell membranes via
ATP binding cassette transporter (ABCA1)
(6) and scavenger receptor type B class 1
(SR-B1) (7) to lipid-poor apolipoprotein
(apo) AI. This apo is partly derived from the
gut and liver and partly from the intravascu-
lar lipolysis of triglyceride-rich lipoproteins.
The subsequent steps of RCT include cho-
lesterol esterification by lecithin-cholesterol
acyl transferase (LCAT) (8) and the transfer
of cholesteryl ester to triglyceride-rich lipo-
proteins by cholesteryl ester transfer protein
(CETP) (9). Lastly, cholesteryl ester can be
transferred to the liver directly from HDL
through SR-B1 receptors (7) and indirectly
from apo B-containing lipoproteins through
LDL receptors (10) and LDL receptor-re-
lated proteins (11). The action of CETP on
HDL facilitates the LCAT reaction rate (12)
and hence the cell cholesterol efflux rate.
Also, the combined action of CETP and
hepatic lipase on mature HDL2 regenerates
HDL3 and pre-beta HDL, sub-fractions that
are better acceptors for cell cholesterol (9).
Plasma HDL levels are modulated by
several environmental and genetic factors.
Genetic studies on different populations have
suggested that the contribution of the genetic
component to variation in HDL levels is
large but varies widely: 44 (13), 65 (14), and
83% (15). Experimental investigation of the
genetic determinants of HDL levels and ath-
erosclerosis has been greatly facilitated by
models of genetically modified mice. The
overexpression of apo AI in transgenic mice
attenuated atherogenesis in the wild-type
background and in atherosclerosis-suscep-
tible strains such as apo E knockout mice
(16,17). Separate overexpression of LCAT
(18) or CETP (19) aggravated atherogenesis
whereas, in combination, CETP and LCAT
expression in double-transgenic mice reduced
the severity of atherosclerosis seen in LCAT
single-transgenic mice (18).
The aim of this study was to investigate
whether the separate or combined overex-
pression of apo AI, LCAT and CETP influ-
ences the development of diet-induced ath-
erosclerosis in aged mice.
Material and Methods
Animal protocols
The animal protocols were approved by
the Ethics Committee in Animal Experimen-
tation of the Institution (CEEA/UNICAMP)
and followed the Principles of Laboratory
Animal Care (NIH publication No. 85-23,
revised 1985). The parental mice expressing
human apo AI, LCAT and CETP transgenes
have been described elsewhere (20-22) and
were derived from colonies maintained by
Dr. A.R. Tall (Columbia University, New
York, NY, USA). Two rounds of mating
were necessary to generate the eight geno-
types of mice used: LCAT, AI, CETP, LCAT/
AI, LCAT/CETP, AI/CETP, LCAT/AI/CETP
transgenic and non-transgenic mice. The ge-
notypic screening was done as previously
described (20-22), but only at the end of the
study. All generated male and female mice
aged 18 ± 2 months (N = 95) were placed on
an atherogenic high fat, high cholesterol diet
containing 20% fat, 1.25% cholesterol, and
0.5% cholic acid (Cat. #611208; Dyets, Inc.,
Bethlehem, PA, USA) for 16 weeks. After
this period, the mice were anesthetized with
ketamine (50 mg/kg, ip, Ketalar; Parke-Davis,
São Paulo, SP, Brazil) and xylazine (10 mg/
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kg, ip, Rompum; Bayer S.A., São Paulo, SP,
Brazil), and blood samples were drawn from
the retro-orbital plexus into heparinized hem-
atocrit tubes before perfusing and excising
the hearts. Eighteen mice (19%) died during
the diet period, probably because of liver
disease since, at the end of the study, all mice
showed signals of hepatic steatosis and had
gallbladders full of gallstones. Five mice
were excluded from the study because of
technical problems during the histological
processing of the heart and one was ex-
cluded because of inconclusive genotyping.
The plasma levels of triacylglycerol and to-
tal cholesterol were determined by enzy-
matic methods according to manufacturer
instructions (Roche Diagnostics GmbH, In-
dianapolis, IN, USA). HDL-cholesterol was
determined by the homogeneous assay
(PEGME method) using an automated sys-
tem (Hitachi 917; Roche).
Histological analysis of atherosclerotic
lesions
The hearts of anesthetized mice were
perfused in situ with phosphate-buffered
saline (PBS) followed by 10% PBS-buffered
formaldehyde, and then excised and fixed in
10% formaldehyde for at least two days. The
hearts were then embedded sequentially in
5, 10, and 25% gelatin. Processing and stain-
ing were done according to Paigen et al. (23).
The lipid-stained lesions were quantified as
described by Rubin et al. (16) using Image
Pro Plus software (version 3.0) for image
analysis (Media Cybernetics, Silver Spring,
MD, USA). The slides were read before
genotype identification. The areas of the
lesions were expressed as the sum of the
lesions in six 10 µm-sections, 80 µm apart
along 480 µm of aorta. Because several other
studies have revealed a predilection for the
development of lesions in the aortic root, the
segment chosen for analysis extended from
beyond the aortic sinus up to the point where
the aorta first becomes rounded (16).
Statistical analysis
Data are reported as means ± SEM and
were analyzed by the Kruskal-Wallis test for
multiple comparisons and the Mann-Whit-
ney test for two-group comparisons. The
Spearman test was used to correlate the vari-
ables with the lesion size. Hierarchical, mul-
tiple linear regression analysis was used to
assess the influence of specific genotypes,
sex, plasma triglycerides, total cholesterol,
and HDL-cholesterol concentrations (inde-
pendent variables) on the size of the athero-
sclerotic lesion (dependent variable). These
results are reported as coefficient of determi-
nation (R2), which indicates the percentage
of variation in the dependent variable that
can be explained by the independent vari-
ables. Multiple logistic regression analysis
was used to assess the risk of developing
atherosclerotic lesions larger than the 50th
percentile (median). The level of signifi-
cance was established as P ≤ 0.05 and data
were considered to be marginally significant
at 0.05 < P < 0.10. All statistical analyses
were done using the SAS statistical software
package (version 8).
Results
Table 1 shows the plasma lipid and HDL-
cholesterol concentrations of the eight geno-
typic groups expressing apo AI, CETP and
LCAT or their combinations. None of the
mice developed hypercholesterolemia after
4 months on the high fat, high cholesterol,
cholate-containing diet. Indeed, the plasma
cholesterol levels of wild-type C57Bl6 mice
fed this same diet for 120 days did not ex-
ceed 200 mg/dl (24). Multiple comparisons
by the Kruskal-Wallis test showed no major
differences in the total cholesterol, triglycer-
ide and HDL-cholesterol levels of the groups,
or in the total cholesterol/HDL and HDL/
non-HDL-cholesterol ratios. Thus, the ex-
pected phenotypes of increased HDL levels
in mice overexpressing apo AI and LCAT
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and decreased HDL levels in mice express-
ing CETP were not observed after 4 months
on the atherogenic diet. Previous studies
(25-27) have shown that the HDL-lowering
effect of CETP expression is not observed
after treatment with this atherogenic diet or
in endogenous hypercholesterolemia result-
ing from LDL receptor gene knockout.
The severity of the diet-induced athero-
sclerosis was assessed by morphometric anal-
ysis of the lipid-stained areas in the aortic
roots (Figure 1). The average size of the
atherosclerotic lesions in AI mice was three-
fold smaller than in CETP/AI and LCAT/AI
mice, and four-fold smaller than in LCAT
mice. Despite these striking differences, con-
ventional nonparametric analysis of vari-
ance detected no significant effect of the
eight distinct genotypes on the atheroscle-
rotic lesion size. However, using pairwise
comparisons, the lesion size in apo AI mice
was significantly smaller than in CETP/AI
(P = 0.05) and LCAT/AI (P = 0.02) mice and
marginally significantly smaller than in
LCAT mice (P = 0.09).
Univariate correlation analysis of com-
bined groups (Table 2) showed that lesion
size correlated positively with total choles-
terol, HDL and non-HDL levels, and with
the total cholesterol/HDL ratio, and nega-
tively with the HDL/non-HDL ratio. When
each group was tested separately, lesion size
Table 1. Plasma lipid and lipoprotein concentrations in mice expressing combinations of apo AI, LCAT and
CETP transgenes after 4 months on a high fat, high cholesterol cholate-containing diet.
Groups N TG Chol HDL-Chol non-HDL-Chol Chol/HDL HDL/non-HDL
Non-Tg 12 59 ± 8 124 ± 18 76 ± 5 48 ± 11 1.6 ± 0.07 2.0 ± 0.28
CETP 10 53 ± 6 126 ± 9 80 ± 4 46 ± 5 1.6 ± 0.05 1.9 ± 0.17
LCAT 5 70 ± 11 147 ± 37 89 ± 18 58 ± 19 1.6 ± 0.07 1.8 ± 0.21
AI 12 68 ± 6 132 ± 10 84 ± 6 43 ± 4 1.5 ± 0.03 2.0 ± 0.13
CETP/LCAT 7 54 ± 5 107 ± 11 72 ± 6 37 ± 6 1.5 ± 0.05 2.1 ± 0.34
CETP/AI 15 59 ± 4 128 ± 12 75 ± 6 53 ± 6 1.7 ± 0.06 1.6 ± 0.19
LCAT/AI 8 49 ± 4 128 ± 24 69 ± 5 66 ± 28 2.0 ± 0.06 1.7 ± 0.35
CETP/LCAT/AI 7 58 ± 5 159 ± 17 85 ± 4 61 ± 10 1.7 ± 0.12 1.6 ± 0.32
Data are reported as means ± SEM (mg/dl). Apo AI = apolipoprotein AI; LCAT = lecithin-cholesterol acyl
transferase; CETP = cholesteryl ester transfer protein; Non-Tg = non-transgenic; TG = triglycerides; Chol =
cholesterol.
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Figure 1. Area of aortic athero-
sclerotic lesions in aged CETP,
apo AI and LCAT single- and
multiple-transgenic and non-
transgenic mice after 16 weeks
on a high fat, high cholesterol,
cholate-containing diet. The col-
umns represent the mean ±
SEM of the number of mice indi-
cated below the abscissa (in pa-
rentheses). Apo AI = apolipopro-
tein AI; LCAT = lecithin-choles-
terol acyl transferase; CETP =
cholesteryl ester transfer pro-
tein; non-Tg = non-transgenic.
*P = 0.02 between apo AI and
LCAT/AI mice, P = 0.05 between
apo AI and CETP/AI, and P =
0.09 between apo AI and LCAT
(Mann-Whitney test).
*
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was positively correlated with total choles-
terol, non-HDL-cholesterol and HDL-cho-
lesterol levels in LCAT transgenic mice,
indicating that HDL was not protective in
these mice. In LCAT/AI mice, lesion size
was inversely correlated with HDL-choles-
terol levels, showing that apo AI expression
in LCAT mice markedly changed the asso-
ciation between lesion size and HDL-cho-
lesterol.
Hierarchical multiple regression analy-
ses (Table 3) showed that the independent
variables: cholesterol, HDL, non-HDL, HDL/
non-HDL, triglycerides, genotypes or trans-
genes, and sex, could explain part of the
variation in the size of the atherosclerotic
lesion (dependent variable) with 97-99.9%
confidence. Model I predicted that, regard-
less of the genotypes, total cholesterol and
HDL-cholesterol together explain 11% of
the variation in lesion size. The relationships
that included specific genotypes with the
power to influence lesion size are shown in
models II to VI. The expression of apo AI
(model V) and CETP (model VI) reduced
lesion size, whereas the expression of LCAT
(model IV) and LCAT/AI (models II and III)
had the opposite effect. Male mice had
smaller lesions (models II, IV, V, and VI), as
previously reported (28).
Table 2. Univariate correlations between the atherosclerotic lesion area and the plasma total and lipoprotein
cholesterol levels.
Groups N Chol HDL-Chol non-HDL-Chol Chol/HDL HDL/non-HDL
All 71 0.40 (0.0006) 0.26 (0.003) 0.45 (0.0001) 0.38 (0.002) -0.29 (0.018)
LCAT 5 0.93 (0.02) 0.92 (0.03) 0.94 (0.02) NS NS
LCAT/AI 7 NS -0.79 (0.058) NS NS NS
Data are reported as Spearman correlation coefficients (r) with P values in parentheses. LCAT = lecithin-
cholesterol acyl transferase; apo AI = apolipoprotein AI; Chol = cholesterol; NS = nonsignificant.
Table 3. Influence (coefficient of determination, R2) of plasma lipids, lipoproteins, genotypes, and sex on the
atherosclerotic lesion area in mice expressing combinations of apo AI, LCAT and CETP transgenes.
Multiple linear regression models Significant variables P value Cumulative R2
I. Regardless of the genotypes Chol 0.03 0.11
log (lesion area) = 2.4 + log (Chol) - 2.68 log (HDL) HDL-Chol
II. Each genotype vs non-Tg LCAT/AI genotype 0.003 0.13
Lesion area = 22.2 + 18.0 LCAT/AI - 13.6 sex sex (male)
III. Each genotype vs non-Tg LCAT/AI genotype 0.02 0.12
Lesion area = 29.0 + 16.7 LCAT/AI - 6.9 HDL/non-HDL HDL/non-HDL
IV. Presence vs absence of LCAT transgene LCAT transgene 0.005 0.16
log (lesion area) = 2.7 + 0.45 LCAT - 0.85 sex sex (male)
V. Presence vs absence of AI transgene apo AI transgene 0.0006 0.22
Lesion area = 2.14 - 1.89 AI + 0.20 Chol - 13.77 sex Chol, sex (male)
VI. Presence vs absence of CETP transgene CETP transgene 0.01 0.13
log (lesion area) = 2.99 - 0.18 CETP - 0.84 sex sex (male)
Independent variables: total cholesterol (Chol), HDL-Chol, non-HDL-Chol, HDL/non-HDL, triglycerides, geno-
types or transgenes, and sex (male/female). apo AI = apolipoprotein AI; LCAT = lecithin-cholesterol acyl
transferase; CETP = cholesteryl ester transfer protein; non-Tg = non-transgenic.
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The quantitative interpretation of these
models is as follows:
Model I. Regardless of the genotypes, a
1% elevation in cholesterol levels increases
the lesion size by 2.4% when HDL levels are
maintained, and a 1% increase in HDL levels
decreases the lesion size by 2.7% when cho-
lesterol levels are maintained.
Model II. The LCAT/AI genotype in-
creases the lesion size by 18,000 units as
compared to non-transgenic animals of each
gender. The lesion size is about 14,000 units
smaller in males than in females in a given
genotype.
Model III. For the same HDL/non-HDL
ratio, the LCAT/AI genotype increases the
lesion size by about 17,000 units relative to
non-transgenic animals. An increase of 1
unit in the HDL/non-HDL ratio decreases
the lesion size by about 7000 units in a given
genotype.
Model IV. For the same sex, the LCAT
expression increases the lesion size by 56.8%
compared to all mice not expressing LCAT.
For a given genotype, male mice show a
57.3% decrease in lesion size.
Model V. For a given sex with the same
cholesterol levels, apo AI expression reduces
lesion size by about 1900 units compared to
all mice that did not express apo AI. For a
given genotype, an increase of 1 mg/dl in the
cholesterol concentration increases lesion
size by 200 units and male sex decreases
lesion size by 14,000 units.
Model VI. For the same sex, CETP ex-
pression decreases lesion size by 16.5% com-
pared to all mice not expressing CETP, and
male sex decreases the size of lesions by
57% in a given genotype.
Logistic regression analysis (Table 4) re-
vealed that the risk of developing atheroscle-
rotic lesions larger than the median value
was 4.3-fold lower for apo AI transgenic
mice than for non-transgenic mice, and 3.0-
fold lower for male than for female mice.
Discussion
Multiple linear regression models showed
that cholesterol, HDL-cholesterol, sex and
the expression of RCT genes explained 11-
22% of the variation in the size of the diet-
induced atherosclerotic lesions in transgenic
mice. Since the environment, age, weight,
and diet did not vary among groups, the rest
of the variation in lesion size must be ex-
plained by other genetic factors not con-
trolled in this study. Interactions between
the transgenes studied and other genes that
potentially modify the susceptibility to ath-
erosclerosis were not investigated. Recently,
Stein et al. (29) provided evidence of a puta-
tive genetic basis for resistance to athero-
sclerosis. The proposed mechanism would
involve genes controlling lipoprotein me-
tabolism such as the ABC gene family, apo
E, class A and B scavenger receptors, as well
as inflammatory and oxidative stress-respon-
sive genes.
Some of the associations found here were
expected, such as the negative impact of
total cholesterol concentrations and the pro-
tective effects of HDL-cholesterol and HDL/
non-HDL ratios on the severity of the dis-
ease (uni- and multivariate analyses; Tables
2 and 3). The atheroprotective role of HDL
has been well documented in animal (16,
17,30) and human (1,2) studies. Although
the mice studied here did not present a lipemic
phenotype, the interplay of the plasma con-
centrations of apo AI, LCAT and CETP
partly explained the extent of the diet-in-
duced atherosclerotic lesions. The strongest
Table 4. Odds ratio (OR) and 95% confidence interval (CI) relating the prevalence of an
atherosclerotic lesion greater than the 50th percentile and specific genotypes in mice
expressing combinations of apolipoprotein (apo) AI, lecithin-cholesterol acyl trans-
ferase, and cholesteryl ester transfer protein.
Effect Point estimate 95% CI P value OR
Sex (male) 0.329 0.12-0.90 0.029 -3.04
Apo AI genotype 0.232 0.05-1.00 0.050 -4.31
Multiple logistic regression covariates: cholesterol (Chol), triglycerides, HDL, HDL/
non-HDL, Chol/HDL.
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genetic effect was detected in the LCAT/AI
genotype, which, in the absence of CETP,
worsened atherosclerosis when compared to
non-transgenic mice (Table 3, models II and
III). The CETP genotype per se had a weak
effect, but sufficient to eliminate the delete-
rious effect of the LCAT and LCAT/AI geno-
types since the co-expression of CETP/LCAT
and CETP/LCAT/AI prevented the increase
in their lesion size. The expression of apo AI
alone had a beneficial effect, as seen in
paired comparisons (Figure 1) and by multi-
variate analysis (Table 3, model V). This
beneficial role was confirmed by logistic
regression analysis, which indicated a lower
risk of developing larger lesion sizes (above
the 50th percentile) in the AI group when
compared to non-transgenic mice. Surpris-
ingly, the expression of apo AI was insuffi-
cient to improve the atherogenic effect of
LCAT when both transgenes were co-ex-
pressed. The reason for this may be related to
an increased cholesterol esterification rate in
HDL in the absence of an efficient mechan-
ism for cholesteryl ester removal. This would
lower the hepatic cholesteryl ester uptake
and the rate of regeneration of HDL sub-
fractions that are good cell cholesterol ac-
ceptors. Indeed, Collet et al. (22) showed
that the fractional catabolic rate of HDL-
cholesteryl ester in LCAT/AI mice was mark-
edly lower than in AI, AI/CETP and LCAT/
AI/CETP mice, thus supporting the idea that
CETP expression in LCAT/AI mice has an
anti-atherogenic role by increasing the rate
of HDL-cholesteryl ester removal from
plasma. The harmful effect of LCAT over-
expression and its correction by CETP ex-
pression have also been described by Foger
et al. (18). However, the atherogenic effect
of LCAT/AI expression was unsuspected
and neutralization of this harmful effect by
CETP expression is now demonstrated for
the LCAT/AI background.
In a study of the effects of up-regulating
individual steps of the RCT (7 α hydroxy-
lase, SR-BI, LCAT, and apo AI), Alam et al.
(31) showed that the cholesterol flux through
the entire RCT pathway was not increased.
Thus, increasing each step per se does not
necessarily guarantee protection against ath-
erosclerosis. We showed here that the ex-
pression of LCAT and LCAT/AI resulted in
a higher risk of developing atherosclerosis,
while the expression of CETP in these back-
grounds neutralized this atherogenic scenario,
and that apo AI overexpression reduced the
risk of developing large size atherosclerotic
lesions.
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